676448-17-2

Usage

Uses

Used in Biochemical Research:
4-Bromoindole-1-carboxylic Acid Tert-Butyl Ester is used as a research compound for its unique structural properties, which allow for the investigation of various biochemical interactions and processes.
Used in Organic Synthesis:
4-Bromoindole-1-carboxylic Acid Tert-Butyl Ester is used as an intermediate in the synthesis of more complex organic molecules, particularly those that require the indole core with a bromine substitution and a tert-butyl ester group. This makes it a valuable building block in the development of new pharmaceuticals, agrochemicals, and other specialty chemicals.

InChI:InChI=1/C12H13BrN2O2/c1-12(2,3)17-11(16)15-10-6-4-5-9(13)8(10)7-14-15/h4-7H,1-3H3

Upstream product

• 52488-36-5 4-bromo-1H-indole 
• 34619-03-9 tert-butyldicarbonate 
• 1195931-67-9 tert-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-1H-indole-1-carboxylate 
• 6627-89-0 tert-butyl phenyl carbonate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 252978-89-5 4-(1H-indol-4-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 957034-29-6 4-bromo-1-(tert-butoxycarbonyl)-1H-indol-2-ylboronic acid 
• 893441-86-6 1,1-dimethylethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate 
• 460096-34-8 tert-butyl 4-formyl-1H-indole-1-carboxylate 

Relevant academic research and scientific papers

Rhodium(II)-Catalyzed [4+3] Cyclization of Triazoles with Indole Derivatives and Its Application in the Total Synthesis of (±)-Aurantioclavine

An efficient rhodium(II)-catalyzed [4+3] cyclization reaction of 1-sulfonyl-1,2-3-triazoles and indoles was developed. Azepino[5,4,3- cd]indoles, which are widely distributed in ergot alkaloids with various biological activities, could be obtained in good

Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use

The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Substituted olefin compound, and preparation method and application thereof

The invention provides a substituted olefin compound, and a preparation method and application thereof. Specifically, the application provides a substituted olefin compound, a stereoisomer, prodrug, solvate, and pharmaceutically acceptable salt or ester of the substituted olefin compound, a preparation method of the substituted olefin compound, and an application in preparing medicines for treating diseases relative to an excessive activity of estrogen receptors (such as ERalpha).

An efficient and concise synthesis of Indiacen A and Indiacen B

A novel total synthesis of antimicrobial prenyl indoles, Indiacen A and its chloro analogue Indiacen B has been accomplished by using Horner-Wadsworth-Emmons olefination for terminal conjugated enynes, carboalumination, chlorination and Vilsmeier-Haack formylation as the key transformations.

3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY

Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.

Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-dia

Our structure-activity relationship studies with N6-(2-(4-(1H-indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivatives led to development of a lead compound (-)-21a which exhibited very hi